Keros Therapeutics’ (KROS) Neutral Rating Reiterated at Wedbush

Wedbush reiterated their neutral rating on shares of Keros Therapeutics (NASDAQ:KROS) in a research note released on Tuesday,Benzinga reports. Wedbush currently has a $15.00 price target on the stock.

A number of other brokerages have also issued reports on KROS. Guggenheim restated a “neutral” rating on shares of Keros Therapeutics in a research note on Friday, January 17th. Oppenheimer reduced their price objective on Keros Therapeutics from $63.00 to $23.00 and set an “outperform” rating for the company in a research note on Thursday, January 16th. Truist Financial decreased their target price on Keros Therapeutics from $100.00 to $43.00 and set a “buy” rating for the company in a report on Monday, December 23rd. William Blair downgraded shares of Keros Therapeutics from an “outperform” rating to a “market perform” rating in a report on Thursday, December 12th. Finally, BTIG Research cut shares of Keros Therapeutics from a “buy” rating to a “neutral” rating in a research note on Thursday, December 12th. Six research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $42.33.

Keros Therapeutics Stock Up 2.4 %

KROS opened at $10.28 on Tuesday. The company has a market cap of $416.98 million, a P/E ratio of -1.97 and a beta of 1.39. The firm’s 50-day moving average price is $11.04 and its 200-day moving average price is $33.31. Keros Therapeutics has a 52-week low of $9.41 and a 52-week high of $72.37.

Keros Therapeutics (NASDAQ:KROS) last issued its quarterly earnings results on Wednesday, February 26th. The company reported ($1.14) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.36) by $0.22. Keros Therapeutics had a negative net margin of 27,890.94% and a negative return on equity of 41.74%. The business had revenue of $3.04 million for the quarter, compared to analyst estimates of $37.32 million. On average, research analysts anticipate that Keros Therapeutics will post -4.74 EPS for the current fiscal year.

Institutional Investors Weigh In On Keros Therapeutics

Several hedge funds have recently modified their holdings of the company. Vanguard Group Inc. increased its stake in shares of Keros Therapeutics by 5.4% in the 4th quarter. Vanguard Group Inc. now owns 1,957,109 shares of the company’s stock valued at $30,981,000 after purchasing an additional 100,691 shares in the last quarter. Braidwell LP grew its holdings in Keros Therapeutics by 167.9% in the fourth quarter. Braidwell LP now owns 1,894,439 shares of the company’s stock valued at $29,989,000 after purchasing an additional 1,187,199 shares during the period. Darwin Global Management Ltd. increased its position in shares of Keros Therapeutics by 10.7% in the fourth quarter. Darwin Global Management Ltd. now owns 1,687,135 shares of the company’s stock valued at $26,707,000 after buying an additional 163,403 shares in the last quarter. Point72 Asset Management L.P. raised its stake in shares of Keros Therapeutics by 155.9% during the 3rd quarter. Point72 Asset Management L.P. now owns 947,570 shares of the company’s stock worth $55,025,000 after buying an additional 577,220 shares during the period. Finally, Millennium Management LLC raised its stake in shares of Keros Therapeutics by 53.3% during the 4th quarter. Millennium Management LLC now owns 878,159 shares of the company’s stock worth $13,901,000 after buying an additional 305,169 shares during the period. 71.56% of the stock is owned by hedge funds and other institutional investors.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.